The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 14, 2015
Filed:
Jul. 12, 2007
Applicants:
Grant A. Krafft, Glenview, IL (US);
Todd Pray, San Mateo, CA (US);
William F. Goure, Livermore, CA (US);
Inventors:
Grant A. Krafft, Glenview, IL (US);
Todd Pray, San Mateo, CA (US);
William F. Goure, Livermore, CA (US);
Assignee:
Acumen Pharmaceuticals, Inc., Livermore, CA (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/381 (2006.01); A61K 31/4155 (2006.01); A61K 9/20 (2006.01); A61K 9/00 (2006.01); A61K 9/02 (2006.01); A61K 9/14 (2006.01); A61K 31/41 (2006.01); A61K 31/415 (2006.01); C12N 5/0793 (2010.01);
U.S. Cl.
CPC ...
A61K 9/2054 (2013.01); A61K 9/0019 (2013.01); A61K 9/0075 (2013.01); A61K 9/02 (2013.01); A61K 9/146 (2013.01); A61K 9/2059 (2013.01); A61K 31/381 (2013.01); A61K 31/41 (2013.01); A61K 31/415 (2013.01); C12N 5/0619 (2013.01); C12N 2501/999 (2013.01);
Abstract
Disclosed are methods of inhibiting, regulating, and/or modulating the formation of soluble, globular, non-fibrillar, neurotoxic amyloid βoligomers from amyloid βmonomers. Also disclosed are methods of treating a patient suffering from diseases associated with the formation of soluble, globular, non-fibrillar, neurotoxic amyloid βoligomers.